## Tremfya (guselkunmab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	!	MEMBER'S FIRST NA	\ME:	
	/iew (e.g., chart notes o	or lab data, to support the	Attach any additional documentation authorization request). Information	
			☐ URGENT	
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE I	D NUMBER:			
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG): _	ALLERGIES:	
DISCLOSURE AUTHORIZED FOLLOWING LINK: PRIME PATIENT'S AUTHORIZED AUTHORIZED REPRESE	ETHERAPEUTICS.CO	OM/NOPP (IF APPLICABLE):		
AUTHORIZED REPRESE	NIATIVE 5 PHONE N	UWBER.		
PRESCRIBER INFORMA	ATION			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIAL	TY:	EMAIL ADDRESS	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTAC	OFFICE CONTACT PERSON:	
		<u>'</u>		
MEDICATION OR MEDIC	CAL DISPENSING INF	ORMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFIL	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THE		
DURATION OF THERAP	Y (SPECIFIC DATES)	:		
Continued on next page				

© YYYY-YYYY Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 10.1.24 CAT009



## Tremfya (guselkunmab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:			
4 HAS THE DATIENT TRIED ANY	OTHER MEDICATIONS FOR THIS	CONDITIONS			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?  ☐ YES (if yes, complete below) ☐ NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Plaque psoriasis ☐ Psoriatic arthritis ☐ Ulcerative colitis ☐ Other diagnosis:	ICD-10 Code(s):				
<b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug	in combination with a clinical trial?	? 🗌 Yes 🔲 No			
Initial Request: Will the patient be using Tremfya concurrently with another biologic response modifier or immunomodulatory agent? □ Yes □ No  Select if the patient has had at least a 3-month trial and inadequate response to the Humira biosimilar adalimumab-aacf? □ Yes □ No Please submit documentation.  Is Tremfya prescribed by a dermatologist? □ Yes □ No Is Tremfya prescribed by a gastroenterologist? □ Yes □ No					
For Plaque Psoriasis / Psoriatic Arthritis:  Does the patient have plaques covering at least 10% of their body surface area (BSA) or less than 10% of BSA with involvement of palms, soles, head and neck, or genitalia which cause disruption of normal activities?					
Has the patient had an inadequate response to topical therapy (e.g., corticosteroids, anthralin, calcipotriene, tazarotene)?* □ Yes □ No					
Select if the patient has had a trial and inadequate response to the following phototherapy options:  □ Psoralens with UVA light (PUVA)  □ UVB with coal tar					
Has patient had a trial and failure with a three-month course of one of the following conventional disease modifying anti-rheumatic agents (DMARDs) [e.g., methotrexate, acitretin, sulfasalazine [Azulfidine®], leflunamide [Arava®] or hydroxychloroquine or cyclosporine)?  □ Yes □ No Please submit documentation.					



## Tremfya (guselkunmab) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
Does the patient have documentation of a contra therapies indicated for their disease?   Yes  N				
For Ulcerative colitis: Has patient tried and failed at least one of the fo and/or 6-mercaptopurine? □ Yes □ No Please pro	llowing three therapies: corticosteroids, azathioprine ovide documentation.			
Renewal Request: Is prescriber a dermatologist?   Yes   No Is prescriber a rheumatologist?   Yes   No Is Tremfya prescribed by a gastroenterologist?	⊐ Yes □ No			
Is patient continuing to respond to therapy? $\Box$ Y	es □ No <i>Please submit documentation.</i>			
Will patient use requested medication in combinimmunomodulatory agent? □ Yes □ No	nation with another biologic response modifier or			
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered or required information is received.	n all plans. This request may be denied unless all			
	true and accurate to the best of my knowledge. I roup or its designees may perform a routine audit and the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. Verification	on: Date:			
information that is legally privileged. If you are not the	ompanying this transmission contain confidential health ne intended recipient, you are hereby notified that any eliance on the contents of these documents is strictly			

**FAX THIS FORM TO: 800-424-7640** 

prohibited. If you have received this information in error, please notify the sender immediately (via return

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811

Phone: 877-228-7909



FAX) and arrange for the return or destruction of these documents.